Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009–2019

BACKGROUND: Zanamivir is a neuraminidase inhibitor effective against influenza A and B viruses. In 2009, GlaxoSmithKline (GSK) began clinical development of intravenous (IV) zanamivir and initiated a global Compassionate Use Program (CUP) in response to the evolving H1N1 global pandemic. The goal of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang‐Jairaj, Jie, Miller, Irene, Joshi, Aditya, Jayabalan, Tharaka, Peppercorn, Amanda, Zammit‐Tabona, Peter, Oliver, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983904/
https://www.ncbi.nlm.nih.gov/pubmed/34939702
http://dx.doi.org/10.1111/irv.12947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983904/
https://www.ncbi.nlm.nih.gov/pubmed/34939702
http://dx.doi.org/10.1111/irv.12947

Ejemplares similares